查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
T 细胞治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按模式、治疗类型、适应症和地理位置
市场调查报告书
商品编码
1362429

T 细胞治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按模式、治疗类型、适应症和地理位置

T Cell Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type, Indication, and Geography
出版日期: | 出版商: The Insight Partners | 英文 138 Pages | 订单完成后即时交付

价格

根据我们关于「T 细胞治疗市场预测（2020 - 2030 年）、全球和地区份额、趋势和成长机会分析 - 按模式、治疗类型和适应症」的新研究，T 细胞治疗市场规模估值为2022年为27.540亿美元，预计到2030年将达到90.3501亿美元。预计2020-2030年复合年增长率为16.0%。

T细胞疗法是最有前景的癌症治疗方法之一，每年都会进行越来越多的临床前和临床研究以增加其应用。 CAR T 细胞疗法也引起了肿瘤学家和学者的兴趣。全球癌症负担日益加重以及 T 细胞疗法获批数量不断增加，推动了 T 细胞疗法市场的成长。此外，临床试验中汽车 T 细胞疗法数量的增加预计将推动未来几年 T 细胞疗法市场的成长。

目前 CAR T 细胞疗法前景广阔，拥有多种药物批准、丰富的产品线以及许多正在进行的临床试验。 CAR T 细胞疗法的管道处于临床开发的不同阶段；主要製药公司正在努力推进 CAR T 细胞治疗竞争领域的管道空间和未来成长潜力。

2022 年11 月，Peter MacCallum 癌症中心和Cartherics Pty Ltd 签订了合作开发计画协议(CDPA)，开发Cartherics 专有的自体CAR T 细胞疗法(CTH-001)，用于治疗皮肤T 细胞淋巴瘤(CTCL) 。合作研究的关键面向是建立CTH-001的临床规模生产并进行I期临床试验。最初将招募 6 名难治性 CTCL 患者。

JW Therapeutics 药物 JWCAR029 是一款针对 CD19 的 CAR T 细胞产品，旨在治疗晚期淋巴瘤和白血病。该分子目前正处于开发的第二阶段。 JWCAR029 最初被研究用于治疗 B 细胞恶性肿瘤，重点是復发性和难治性 DLBCL。

吉利德科学公司的药物 KTE-X19 是一种正在研究的自体 CD19 CAR T 细胞疗法。该药物采用 XLP 製程生产，包括 T 细胞选择和淋巴细胞富集。正在研究 KTE-X19 的某些 B 细胞恶性肿瘤需要淋巴细胞富集。 KTE-X19目前正在进行治疗成人和儿童急性淋巴性白血病的II期临床试验。 FDA 已批准 Brexucabtagene autoleucel（以前称为 KTE-X19；Tecartus）用于治疗患有復发或难治性套细胞淋巴瘤 (MCL) 的成年患者。

ZUMA-3 是一项1/2 期研究，评估KTE-X19（一种自体抗CD19 CAR T 细胞疗法）治疗成人復发/难治性(R/R) B 细胞急性淋巴细胞白血病(B-ALL)的效果。

Descartes-11 是一种 mRNA CAR T 细胞疗法，已进入针对新诊断的高风险多发性骨髓瘤 (MM) 患者的 II 期临床试验。 Descartes-11 可瞬时表达 CAR T 细胞分子，并避免这些治疗药物的一些特征毒性。一项针对 18 名患者的 I 期研究 (NCT03994705) 已经开展，结果显示没有证据表明细胞激素释放综合征或神经毒性不良事件通常与 CAR T 细胞治疗相关。

因此，上述CAR-T细胞疗法的管线正成为T细胞疗法市场的新趋势。

按方式，T 细胞治疗市场洞察

根据模式，T 细胞治疗市场分为研究型和商业化型。 2022年，商业化细分市场占据更大的市场份额。此外，预计同一细分市场在预测期内将成长最快。产品发布的增加以及人们对 T 细胞治疗癌症治疗益处的认识的提高，推动了商业化领域的成长。

按治疗类型划分，基于 T 细胞治疗市场的见解

根据治疗类型，T 细胞治疗市场分为 CAR T 细胞治疗和基于 T 细胞受体 (TCR) 的治疗。 2022年，CAR T细胞治疗领域占据更大的市场。此外，同一细分市场在预测期内将以显着的速度成长。在嵌合抗原受体（CAR）T细胞治疗技术中，从患者身上获得的T细胞经过人工生物工程改造，表达能够辨识并附着在肿瘤细胞上的CAR。这些公司正在进行策略发展，例如合作、扩张、协议、伙伴关係以及 CAR T 细胞领域营运公司推出的新产品，从而推动 T 细胞治疗市场的成长。例如，2022年，FDA批准了Janssen Biotech, Inc.生产的CARVYKTI。CARVYKTI是一种名为CAR-T的疗法，代表嵌合抗原受体T细胞。 CARVYKTI（ciltacabtagene autoleucel）是一种用于治疗患有骨髓癌（称为多发性骨髓瘤）的成年患者的治疗方法。 CARVYKTI 治疗经过四种或更多种前线治疗后復发或难治性多发性骨髓瘤的成年患者，包括蛋白酶体抑制剂、免疫调节剂和抗 CD38 单株抗体。

世界卫生组织 (WHO)、欧洲癌症患者联盟和国家癌症研究所是在准备 T 细胞治疗市场报告时提到的一些主要的主要和次要来源。

目录

第 1 章：简介

  • Insight Partners 研究报告指南
  • 市场区隔

第 2 章：执行摘要

  • 重要见解
  • T 细胞治疗市场（依地理位置）

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：T 细胞治疗市场格局

  • 概述
  • PEST分析
    • 全球PEST分析

第 5 章：T 细胞治疗市场 - 主要产业动态

  • 市场驱动因素：
    • 全球癌症负担日益加重
    • T 细胞疗法获批数量不断增加
  • 市场限制
    • CAR T 细胞疗法的副作用
  • 市场机会
    • T 细胞治疗投资不断增加
  • 未来的趋势
    • 临床试验中 CAR T 细胞疗法的数量不断增加
  • 影响分析：

第 6 章：T 细胞治疗市场 - 全球市场分析

  • T 细胞治疗市场收入，2022 - 2030

第 7 章：全球 T 细胞治疗市场 - 收入和 2030 年预测 - 按方式

  • 概述
  • 2022 年和 2030 年 T 细胞治疗市场收入份额（按方式）（%）
  • 研究
  • 商业化

第 8 章：全球 T 细胞治疗市场 - 2030 年收入和预测 - 按治疗类型

  • 概述
  • 2022 年和 2030 年按治疗类型分類的 T 细胞治疗市场收入份额 (%)
  • CAR T细胞疗法
  • 基于 T 细胞受体 (TCR)

第 9 章：全球 T 细胞治疗市场 - 收入和 2030 年预测 - 按指标

  • 概述
  • 2022 年和 2030 年按适应症分類的 T 细胞治疗市场收入份额 (%)
  • 血液系统恶性肿瘤
  • 实体肿瘤

第 10 章：T 细胞治疗市场 - 地理分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 以色列
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西

第 11 章：T 细胞治疗市场-产业格局

  • 概述
  • T细胞治疗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 12 章：公司简介

  • Immunocore Holdings Plc
  • Legend Biotech Corp
  • Janssen Global Services LLC
  • Gilead Sciences Inc
  • Bristol-Myers Squibb Co
  • Bluebird Bio Inc
  • Novartis AG
  • JW (Cayman) Therapeutics Co Ltd
  • Cartesian Therapeutics Inc
  • Innovent Biologics Inc

第 13 章：附录

  • 关于我们
  • 专业术语
Product Code: TIPRE00024331

According to our new research study on "T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Modality, Therapy Type, and Indication," the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020-2030.

One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.

The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T cell therapy market.

By Modality, T Cell Therapy Market-Based Insights

Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.

By Therapy Type, T Cell Therapy Market -Based Insights

Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T-which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the T cell therapy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global T cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global T cell therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 T Cell Therapy Market, by Geography (US$ Million)

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. T Cell Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis

5. T Cell Therapy Market - Key Industry Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Growing Burden of Cancer Worldwide
    • 5.1.2 Increasing Number of T-Cell Therapy Approvals
  • 5.2 Market Restraints
    • 5.2.1 Side-effects of CAR T-Cell Therapy
  • 5.3 Market Opportunities
    • 5.3.1 Growing Investment in T-Cell Therapy
  • 5.4 Future Trends
    • 5.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
  • 5.5 Impact Analysis:

6. T Cell Therapy Market - Global Market Analysis

  • 6.1 T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality

  • 7.1 Overview
  • 7.2 T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
  • 7.3 Research
    • 7.3.1 Overview
    • 7.3.2 Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Commercialized
    • 7.4.1 Overview
    • 7.4.2 Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

  • 8.1 Overview
  • 8.2 T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
  • 8.3 CAR T-cell Therapy
    • 8.3.1 Overview
    • 8.3.2 CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 T-cell Receptor (TCR)-based
    • 8.4.1 Overview
    • 8.4.2 T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

  • 9.1 Overview
  • 9.2 T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
  • 9.3 Hematologic Malignancies
    • 9.3.1 Overview
    • 9.3.2 Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.3.3 Global T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
  • 9.4 Solid Tumor
    • 9.4.1 Overview
    • 9.4.2 Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. T Cell Therapy Market - Geographical Analysis

  • 10.1 North America T Cell Therapy Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.1.4 North America: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.1.5 North America: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.5.1 North America: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.1.5.2 North America T Cell Therapy Market, by Country
      • 10.1.5.3 US
        • 10.1.5.3.1 US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.5.3.2 US: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.1.5.3.3 US: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.5.3.4 US: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.5.3.4.1 US: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.1.5.4 Canada
        • 10.1.5.4.1 Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.5.4.2 Canada: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.1.5.4.3 Canada: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.5.4.4 Canada: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.5.4.4.1 Canada: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.1.5.5 Mexico
        • 10.1.5.5.1 Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.5.5.2 Mexico: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.1.5.5.3 Mexico: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.1.5.5.4 Mexico: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.1.5.5.4.1 Mexico: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.2 Europe T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.2.1 Overview
    • 10.2.2 Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.2.4 Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.2.5 Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.2.5.1 Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.2 Europe T Cell Therapy Market, by Country
      • 10.2.5.3 UK
        • 10.2.5.3.1 UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.3.2 UK: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.3.3 UK: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.3.4 UK: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.3.4.1 UK: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.4 Germany
        • 10.2.5.4.1 Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.4.2 Germany: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.4.3 Germany: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.4.4 Germany: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.4.4.1 Germany: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.5 France
        • 10.2.5.5.1 France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.5.2 France: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.5.3 France: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.5.4 France: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.5.4.1 France: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.6 Italy
        • 10.2.5.6.1 Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.6.2 Italy: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.6.3 Italy: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.6.4 Italy: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.6.4.1 Italy: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.7 Spain
        • 10.2.5.7.1 Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.7.2 Spain: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.7.3 Spain: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.7.4 Spain: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.7.4.1 Spain: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.2.5.8 Rest of Europe
        • 10.2.5.8.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.5.8.2 Rest of Europe: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.2.5.8.3 Rest of Europe: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.2.5.8.4 Rest of Europe: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.2.5.8.4.1 Rest of Europe: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.3 Asia Pacific T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.3.4 Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.3.5 Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.3.5.1 Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.2 Asia Pacific T Cell Therapy Market, by Country
      • 10.3.5.3 China
        • 10.3.5.3.1 China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.3.2 China: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.3.3 China: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.3.4 China: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.3.4.1 China: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.4 Japan
        • 10.3.5.4.1 Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.4.2 Japan: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.4.3 Japan: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.4.4 Japan: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.4.4.1 Japan: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.5 Australia
        • 10.3.5.5.1 Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.5.2 Australia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.5.3 Australia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.5.4 Australia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.5.4.1 Australia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.6 South Korea
        • 10.3.5.6.1 South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.6.2 South Korea: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.6.3 South Korea: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.6.4 South Korea: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.6.4.1 South Korea: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.3.5.7 Rest of Asia Pacific
        • 10.3.5.7.1 Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.5.7.2 Rest of Asia Pacific: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.3.5.7.3 Rest of Asia Pacific: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.3.5.7.4 Rest of Asia Pacific: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.3.5.7.4.1 Rest of Asia Pacific: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.4 Middle East & Africa T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.4.1 Overview
    • 10.4.2 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 10.4.4 Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 10.4.5 Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 10.4.5.1 Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.4.5.2 Middle East & Africa T Cell Therapy Market, by Country
      • 10.4.5.3 Saudi Arabia
        • 10.4.5.3.1 Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.3.2 Saudi Arabia: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.4.5.3.3 Saudi Arabia: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.3.4 Saudi Arabia: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.3.4.1 Saudi Arabia: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.4.5.4 Israel
        • 10.4.5.4.1 Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.4.2 Israel: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.4.5.4.3 Israel: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.4.4 Israel: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.4.4.1 Israel: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
      • 10.4.5.5 Rest of Middle East & Africa
        • 10.4.5.5.1 Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.5.2 Rest of Middle East & Africa: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.4.5.5.3 Rest of Middle East & Africa: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.4.5.5.4 Rest of Middle East & Africa: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.4.5.5.4.1 Rest of Middle East & Africa: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 10.5 South & Central America T Cell Therapy Market, Revenue and Forecast to 2030
    • 10.5.1 Overview
    • 10.5.2 South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
      • 10.5.2.1 Brazil
        • 10.5.2.1.1 Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.2.1.2 Brazil: T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
        • 10.5.2.1.3 Brazil: T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
        • 10.5.2.1.4 Brazil: T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
        • 10.5.2.1.4.1 Brazil: T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

11. T Cell Therapy Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in T Cell Therapy Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Immunocore Holdings Plc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Legend Biotech Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Janssen Global Services LLC
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Gilead Sciences Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bristol-Myers Squibb Co
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Bluebird Bio Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Novartis AG
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 JW (Cayman) Therapeutics Co Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Cartesian Therapeutics Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Innovent Biologics Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. T Cell Therapy Market Segmentation
  • Table 2. Global T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. US T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. US T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Canada T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. UK T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. UK T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Germany T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Germany T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Germany T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Germany T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. France T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. France T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. France T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 34. France T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Italy T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Italy T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Rest of Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 44. Rest of Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 45. Rest of Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 46. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 47. FDA-Approved Autologous CAR T-Cell Therapies Registered in Asia Pacific
  • Table 48. Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 50. Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 51. Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 52. China T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 53. China T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 54. China T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 55. China T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 56. Japan T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 57. Japan T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 58. Japan T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 59. Japan T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 60. Australia T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 61. Australia T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 62. Australia T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 63. Australia T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 64. South Korea T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 65. South Korea T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 66. South Korea T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 67. South Korea T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 68. Rest of Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 69. Rest of Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 70. Rest of Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 71. Rest of Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 72. Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 73. Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 74. Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 75. Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 76. Saudi Arabia T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 77. Saudi Arabia T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 78. Saudi Arabia T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 79. Saudi Arabia T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 80. Israel T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 81. Israel T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 82. Israel T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 83. Israel T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 84. Rest of Middle East & Africa T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 85. Rest of Middle East & Africa T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 86. Rest of Middle East & Africa T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 87. Rest of Middle East & Africa T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 88. Brazil T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
  • Table 89. Brazil T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 90. Brazil T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 91. Brazil T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
  • Table 92. Recent Organic Growth Strategies in T Cell Therapy Market
  • Table 93. Recent Inorganic Growth Strategies in the T Cell Therapy Market
  • Table 94. Glossary of Terms, T Cell Therapy Market

List Of Figures

  • Figure 1. T Cell Therapy Market Segmentation, By Geography
  • Figure 2. Global - PEST Analysis
  • Figure 3. T Cell Therapy Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
  • Figure 6. T Cell Therapy Market Revenue, Geography (US$ Mn), 2022 - 2030
  • Figure 7. T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
  • Figure 8. Research: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Commercialized: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
  • Figure 11. CAR T-cell Therapy: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. T-cell Receptor (TCR)-based: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
  • Figure 14. Hematologic Malignancies: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Solid Tumor: T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America: T Cell Therapy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 17. North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 18. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 19. US T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 20. Canada T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 21. Mexico T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Europe T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
  • Figure 23. Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 25. UK T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Germany T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 27. France T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Italy T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 29. Spain T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Asia Pacific T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
  • Figure 32. Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Asia Pacific T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 34. China T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 35. Japan T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 36. Australia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 37. South Korea T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 38. Rest of Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 39. Middle East & Africa T Cell Therapy Market, by Key Country - Revenue, 2022
  • Figure 40. Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. Middle East & Africa T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
  • Figure 42. Saudi Arabia T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. Israel T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Rest of Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 45. South & Central America T Cell Therapy Market, by Key Country - Revenue, 2022 ($Mn)
  • Figure 46. South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 47. Brazil T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 48. Pre & Post Covid-19 Impact
  • Figure 49. Growth Strategies in T Cell Therapy Market